Main content

    HealthWise KnowledgeBase

    Protease Inhibitors (PIs) for Hepatitis C

    Protease Inhibitors (PIs) for Hepatitis C



    References

    Citations

    1. Poordad F, et al. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine, 364(13): 1195–1206.

    2. Bacon BR, et al. (2011). Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine, 364(13): 1207–1217.

    3. McHutchison JG, et al. (2009). Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine, 360(18): 1827–1838.

    4. McHutchison JG, et al. (2009). Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine, 360(18): 1839–1850.

    5. Singal AK, et al. (2010). Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis, Clinical Gastroenterology and Hepatology, 8(2): 192–199.

    6. Dienstag JL (2010). Chronic viral hepatitis. In GL Mandell et al., eds., Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed., vol. 1, pp. 1593–1670. Philadelphia: Churchill Livingstone Elsevier.




    By: Reference Healthwise Staff Last Revised: May 14, 2012
    Medical Review: Reference E. Gregory Thompson, MD - Internal Medicine
    Reference W. Thomas London, MD - Hepatology


    This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Reference Terms of Use. Reference How this information was developed to help you make better health decisions.


    Topic Contents